Skip to main content
. 2019 Oct 7;116(12):1948–1957. doi: 10.1093/cvr/cvz258

Figure 3.

Figure 3

HAAO blockade decreases atherosclerosis and plasma lipid levels. (A) Schematic overview of the kynurenine pathway and the NCR-631 target 3-HAA 3,4-dioxygenase (HAAO). (B) Twelve-week-old Ldlr−/− mice were fed a western diet and treated three times weekly with NCR-631 or 3-HAA (200 mg/kg) for 8 weeks. A PBS group was used as control (PBS, n = 23; NCR-631, n = 10; and 3-HAA, n = 15). En face % lesion area in the aortic roots. Pooled data from two independent experiments are shown. Representative micrographs of each group. (C) Total cholesterol and (D) triglyceride plasma levels (PBS, n = 22; NCR-631, n = 10; and 3-HAA, n = 15). (E) Mice body weight at the end of treatment (PBS, n = 23; NCR-631, n = 10; and 3-HAA, n = 15). *P < 0.05; **P < 0.01; Kruskal–Wallis ANOVA with Dunn’s post-test. IDO, indoleamine-2,3-dioxygenase; TDO, tryptophan dioxygenase; KAT, kynurenine aminotransferase; KA, kynurenic acid.